Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)Business Wire • 09/04/26
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease TranscriptSeeking Alpha • 09/04/26
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patientsBusiness Wire • 09/03/26
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?Zacks Investment Research • 08/28/26
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026Business Wire • 08/20/26
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS LawBusiness Wire • 08/08/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSPRNewsWire • 08/07/26
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?The Motley Fool • 08/03/26
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/29/26
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 07/29/26
Ionis reports second quarter 2026 financial results and highlights progress on key programsBusiness Wire • 07/29/26
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSSGlobeNewsWire • 07/28/26